PCSK9 Inhibitors (e.g., Repatha): Benefits For Longevity

September 30, 2025/Adrian Blackwell

High cholesterol raises the risk of heart attacks, strokes, and even early death. For some people, diet, exercise, and statins bring cholesterol down, but for many, these are not enough. 

This is why researchers now look closely at PCSK9 (proprotein convertase subtilisin/kexin type 9)  inhibitors. These drugs work by blocking a protein that drives cholesterol higher. As a result, LDL levels drop lower than most treatments can reach. 

🔑Key takeaways

➤ Block the PCSK9 protein to lower LDL cholesterol and reduce the risk of heart disease.

➤ Strong protection against coronary heart disease when natural PCSK9 mutations reduce LDL cholesterol.

➤ Provide treatment options through FDA-approved drugs alirocumab and evolocumab, both given as injections.

➤ Deliver clearer survival benefits with alirocumab, which lowers death risk more than evolocumab in patients with high cholesterol.

➤ Reduce LDL cholesterol and heart events with evolocumab, though studies show mixed results on lowering deaths.

➤ Maintain long-term safety with both drugs, with only mild injection-site reactions reported more often with alirocumab.

What are PCSK9 inhibitors?

PCSK9 inhibitors are cholesterol-lowering drugs that block the PCSK9 protein. PCSK9 inhibitors are a new class of drugs that have changed the way doctors manage heart disease risk. 

According to a study, PCSK9 was unknown until about 20 years ago but is now widely recognized in cardiovascular medicine. PCSK9 plays a central role in lipoprotein metabolism by controlling the degradation of low-density lipoprotein receptors (LDLR). 

When these receptors are blocked, LDL cholesterol stays in the blood and raises the risk of atherosclerotic cardiovascular disease. Discovering this pathway led to PCSK9 inhibitors, turning a genetic finding into a major treatment breakthrough.

Genetic link to cholesterol

According to one study, naturally occurring mutations in the PCSK9 gene reduce LDL cholesterol and provide strong protection against coronary heart disease. 

In the study, 2.6% of Black participants carried nonsense mutations, leading to a 28% reduction in LDL cholesterol and an 88% lower risk of coronary heart disease. Among White participants, 3.2% had a different PCSK9 variant associated with a 15% LDL reduction and a 47% decrease in coronary events. These findings confirmed PCSK9 as a powerful therapeutic target for lowering cholesterol and preventing heart disease.

PCSK9 in the body

According to another study, PCSK9 is produced mainly in the liver but is also expressed in tissues such as the vascular wall, kidneys, and brain. 

In these organs, it may influence neurocognitive processes, immunity, and even neuronal apoptosis. Because of this, researchers emphasize the importance of understanding its broader biological roles, especially as highly effective PCSK9 inhibitors are now in use.

Two types of PCSK9 inhibitors 

The two FDA-approved PCSK9 inhibitors are alirocumab and evolocumab. Both are fully human monoclonal antibodies that bind PCSK9 so LDL receptors stay active longer, which lowers LDL cholesterol substantially.

  1. Alirocumab (Praluent)

Alirocumab is one of the two main PCSK9 inhibitors approved by the FDA. It is given as a shot under the skin. The usual starting dose is 75 mg every two weeks, but another option is 300 mg once a month. If cholesterol levels stay high, doctors may increase the dose to 150 mg every two weeks.

This medicine is used for adults with high cholesterol who are at risk for heart disease. It is also used in people with familial hypercholesterolemia, a condition that causes very high cholesterol from a young age. In some cases, it is combined with other cholesterol-lowering drugs to achieve stronger effects.

  1. Evolocumab (Repatha)

Evolocumab is the second PCSK9 inhibitor approved for use. This is also given as a shot under the skin. Adults can take 140 mg every two weeks or 420 mg once a month. 

Children as young as 10 with familial hypercholesterolemia can also use this treatment. For those with the more severe homozygous type of the disease, the dose can be raised if cholesterol remains high after three months.

Do PCSK9 inhibitors improve survival?

PCSK9 inhibitors’ effect on survival is less clear. Studies on alirocumab and evolocumab show mixed results, with some trials reporting reduced deaths and others showing no clear benefit. This section looks at the evidence on their impact on mortality.

Alirocumab 

In the ODYSSEY OUTCOMES trial, alirocumab significantly reduced deaths compared to placebo in patients with a recent acute coronary syndrome. Over a median of 2.8 years, 3.5% of patients in the alirocumab group died compared to 4.1% in the placebo group. This translated into a hazard ratio of 0.85, showing a 15% relative reduction in risk of death. The benefit was especially strong in those with higher baseline LDL cholesterol levels, where the absolute mortality reduction was greater.

According to another study, mortality benefits with alirocumab became more evident with longer treatment. In patients followed for at least 3 years, the hazard ratio for death was 0.78. This means a 22% lower risk of dying compared with placebo. The analysis also showed that patients with baseline LDL cholesterol of 100 mg/dL or higher had the largest mortality benefit, with a hazard ratio of 0.71. In other words, patients with higher cholesterol levels gained more from therapy.

A study that conducted a Bayesian network meta-analysis of nine randomized controlled trials with 54,311 patients showed that alirocumab was linked to a significant reduction in all-cause mortality. The relative risk was 0.83 compared with the control. 

Evolocumab 

Evolocumab has been studied extensively, but its effect on mortality is less consistent compared with alirocumab. The results depend on trial duration and patient characteristics, and this makes interpretation more complex.

In the FOURIER trial, which included over 27,000 patients with atherosclerotic cardiovascular disease, evolocumab lowered LDL cholesterol and reduced the risk of cardiovascular events during a median follow-up of 2.2 years. However, it did not significantly lower cardiovascular or all-cause mortality in this short timeframe. Some experts believed the trial ended too early, which may have limited its ability to detect mortality benefits. In fact, after more than 2.5 years of follow-up, the rate of all-cause death was slightly higher in the evolocumab group (4.8%) than in the placebo group (4.3%). This unexpected pattern raised concerns that a longer trial might have shown a different outcome.

A large meta-analysis of 41 randomized controlled trials confirmed that evolocumab consistently lowers LDL cholesterol across different baseline levels. But it did not show a significant reduction in cardiovascular mortality, even when baseline LDL cholesterol was above 100 mg/dL. Another pooled analysis of 12 trials with more than 53,000 patients found that evolocumab reduced the risk of major adverse cardiovascular events, heart attack, stroke, and the need for revascularization. Yet, like the earlier studies, it did not lower all-cause or cardiovascular mortality.

✂️ In short

Alirocumab has shown consistent mortality benefits in clinical trials, with up to a 22% reduction in risk of death, especially in patients with higher baseline LDL cholesterol. In contrast, evolocumab lowers LDL and reduces cardiovascular events but has not demonstrated a clear reduction in all-cause or cardiovascular mortality.

Are PCSK9 inhibitors safe long-term?

Researchers have tested PCSK9 inhibitors for many years to check if they are safe for long-term use. Large trials and meta-analyses now provide clear data on how alirocumab and evolocumab perform over time.

Alirocumab

According to a study, alirocumab was shown to be generally safe in long-term use. Their updated meta-analysis assessed adverse events, including serious events, diabetes-related problems, and neurocognitive side effects. They found no overall increase in risk compared with placebo or ezetimibe. 

In fact, alirocumab significantly reduced the risk of serious adverse events, with a risk ratio of 0.937. It also lowered the risk of diabetes-related adverse events, with a risk ratio of 0.9137. The analysis reported that the overall incidence of long-term adverse events was 75.1%, while serious long-term events occurred at a rate of 16.2%. These findings support that alirocumab is safe for extended use and may even reduce some health risks.

In the ODYSSEY OUTCOMES Investigators, alirocumab remained effective and well-tolerated over extended follow-up. In 8,242 patients eligible for 3 to 5 years of placebo-controlled observation, the median follow-up was 3.3 years, totaling 24,610 patient-years. The frequency of adverse events was nearly identical between alirocumab and placebo, with any adverse event reported in 78.3% vs 80.2% of patients, and serious adverse events in 27.5% vs 29.4%. Key safety markers, including:

  • incident diabetes
  • diabetes complications
  • neurocognitive problems
  • elevations in liver enzymes
  • bilirubin, and 
  • creatine phosphokinase

As well as drug discontinuations due to side effects, the study showed that there was no excess risk with alirocumab. The only consistent difference was a slightly higher rate of local injection-site reactions, though these were mild, affected fewer than 5% of patients over 4 years, and mostly occurred in the first 6 months. 

Evolocumab

According to a trial, evolocumab maintained a favorable safety profile in long-term use. In the FOURIER-OLE study, which followed patients for a median of 5 years and up to 8.4 years, evolocumab did not show higher rates of:

  • serious adverse events
  • muscle-related problems
  • new-onset diabetes
  • hemorrhagic stroke, or 
  • neurocognitive issues

Importantly, cardiovascular benefits continued to build over time. Patients who had received evolocumab from the start had a 15% lower risk of cardiovascular death, heart attack, stroke, or hospitalization for unstable angina or revascularization.

The cognitive safety of evolocumab was specifically tested in the EBBINGHAUS substudy of FOURIER. Over 19 months, no significant differences were seen between evolocumab and placebo in executive function, memory, or psychomotor speed.

According to another study, even very low LDL cholesterol achieved with evolocumab plus statins over a median 5.1-year follow-up did not impair cognition. In this study of 473 patients, executive function scores remained stable, with no meaningful differences between those who had always been on evolocumab and those who started later.

AlirocumabEvolocumab
Survival benefitDemonstrated consistent reductions in all-cause mortality, especially in patients with higher baseline LDL cholesterol. Benefits become more evident with longer treatment.No clear mortality benefit. Lowers LDL and reduces cardiovascular events, but trials did not show a significant reduction in all-cause or cardiovascular death.
Safety (Long-term)Generally safe in long-term use. No increase in serious adverse events, diabetes, or neurocognitive issues. Slightly higher rate of mild injection-site reactions early on.Long-term use shows good safety profile. No increase in serious adverse events, diabetes, neurocognitive issues, or muscle problems. Cardiovascular benefits sustained over time.

Wrap up

PCSK9 inhibitors such as alirocumab and evolocumab bring powerful cholesterol-lowering effects, which matter for long-term heart health. The evidence shows alirocumab stands out, with studies linking it to lower mortality, especially in patients with very high LDL cholesterol. 

Evolocumab lowers LDL and reduces cardiovascular events, but its survival benefit remains uncertain in shorter trials. Both drugs, however, have proven safe for long-term use, with no major concerns for diabetes, cognition, or muscle health. 

The true benefit of PCSK9 inhibitors for longevity outcomes lies in how they lower the risk of heart attack and stroke, helping extend life in patients who face the highest cardiovascular risks.

FAQs on PCSK9 inhibitors

How do you take PCSK9 inhibitors?

They’re given as an injection, usually every 2 to 4 weeks. Your provider checks your cholesterol regularly with blood tests.

What are the side effects?

Most people tolerate them well. Common side effects are fatigue, muscle pain, or swelling at the injection site.  

Do PCSK9 inhibitors replace lifestyle changes?

No. You still need a healthy diet, exercise, stress management, and good sleep to protect your heart.

Who should not take PCSK9 inhibitors?

They aren’t for everyone. People with severe liver or kidney disease may need a different approach or dose adjustment.

Sources

  • Cohen, J. C., Boerwinkle, E., Mosley, T. H., Jr, & Hobbs, H. H. (2006). Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. The New England journal of medicine, 354(12), 1264–1272. https://doi.org/10.1056/NEJMoa054013
  • Norata, G. D., Tavori, H., Pirillo, A., Fazio, S., & Catapano, A. L. (2016). Biology of proprotein convertase subtilisin kexin 9: Beyond low-density lipoprotein cholesterol lowering. Cardiovascular Research, 112(1), 429–442. https://doi.org/10.1093/cvr/cvw194
  • Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., & for the ODYSSEY OUTCOMES Committees and Investigators. (2018). Alirocumab and cardiovascular outcomes after acute coronary syndrome. The New England Journal of Medicine, 379(22), 2097–2107. https://doi.org/10.1056/NEJMoa1801174
  • Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Brégeault, M.-F., Dalby, A. J., Diaz, R., & for the ODYSSEY OUTCOMES Committees and Investigators. (2019). Effect of alirocumab on mortality after acute coronary syndromes: An analysis of the ODYSSEY OUTCOMES randomized clinical trial. Circulation, 140(2), 103–112. https://doi.org/10.1161/CIRCULATIONAHA.118.038840
  • Wang, X., Wen, D., Chen, Y., Ma, L., & You, C. (2022). PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: A Bayesian network meta-analysis. Cardiovascular Diabetology, 21, Article 107. https://doi.org/10.1186/s12933-022-01542-4
  • McClintick, D. J., O’Donoghue, M. L., De Ferrari, G. M., Ferreira, J., Ran, X., Im, K., López, J. A. G., Elliott-Davey, M., Wang, B., Monsalvo, M. L., Atar, D., Keech, A., Giugliano, R. P., & Sabatine, M. S. (2024). Long-term efficacy of evolocumab in patients with or without multivessel coronary disease. Journal of the American College of Cardiology, 83(6), 652–664. https://doi.org/10.1016/j.jacc.2023.11.029
  • Ma, H., Ma, W., Liu, Y., Chen, L., & Ding, P. (2025). Effects of alirocumab and evolocumab on cardiovascular mortality and LDL-C: Stratified according to the baseline LDL-C levels. Reviews in Cardiovascular Medicine, 26(4), Article 26980. https://doi.org/10.31083/RCM26980
  • Choi, H. D., & Kim, J. H. (2023). An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors. Cardiovascular therapeutics, 2023, 7362551. https://doi.org/10.1155/2023/7362551
  • Goodman, S. G., Steg, P. G., Poulouin, Y., Bhatt, D. L., Bittner, V. A., Diaz, R., Garon, G., et al. (2023). Long-term efficacy, safety, and tolerability of alirocumab in 8,242 patients eligible for 3 to 5 years of placebo-controlled observation in the ODYSSEY OUTCOMES trial. Journal of the American Heart Association, 12(18), e029216. https://doi.org/10.1161/JAHA.122.029216
  • O’Donoghue, M. L., Giugliano, R. P., Wiviott, S. D., Atar, D., Keech, A., Kuder, J. F., Im, K., … Sabatine, M. S. (2022). Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation, 146(15), 1121–1132. https://doi.org/10.1161/CIRCULATIONAHA.122.061620
  • Giugliano, R. P., Mach, F., Zavitz, K., Kurtz, C., Im, K., Kanevsky, E., Schneider, J., Wang, H., Keech, A., Pedersen, T. R., Sabatine, M. S., Sever, P. S., Robinson, J. G., Honarpour, N., Wasserman, S. M., Ott, B. R., & EBBINGHAUS Investigators (2017). Cognitive Function in a Randomized Trial of Evolocumab. The New England journal of medicine, 377(7), 633–643. https://doi.org/10.1056/NEJMoa1701131
  • Zimerman, A., O’Donoghue, M. L., Ran, X., Im, K., Ott, B. R., Mach, F., Zavitz, K., Kurtz, C. E., Monsalvo, M. L., Wang, B., Atar, D., Keech, A., Sabatine, M. S., & Giugliano, R. P. (2025). Long-Term Cognitive Safety of Achieving Very Low LDL Cholesterol with Evolocumab. NEJM evidence, 4(1), EVIDoa2400112. https://doi.org/10.1056/EVIDoa2400112

Author Bio: Dr. Adrian Blackwell is the founder and CEO of PonteVita Rx, a telehealth practice dedicated to making medication access simpler, more affordable, and less stressful. Licensed to practice medicine in all 50 states and DC, Dr. Blackwell is board certified in obesity medicine and emergency medicine. He combines clinical expertise with personal experience navigating the healthcare system as a patient and parent to children with chronic illnesses. His mission: ensure everyone has access to their necessary medications without unnecessary barriers.

Medical Disclaimer: All the information here, on these videos, YouTube, social media, or in any other format, is for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always consult your personal physician or other qualified health provider with any questions you may have regarding a medical condition. Never replace professional medical advice given to you personally or delay in seeking it because of something you have read or heard on this website. This information is not meant to diagnose, treat, or cure any medical condition. No patient-physician relationship is formed. If you’re my patient, please text me before you make any changes to your medication. If you believe you are having a medical emergency please call 911.

Posted in